| Soluble Epoxide Hydrolase 2 (EPHX2) | |
| Biomarker for Tumor | |
Alternative name:
|
|
|
|
| Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in Spontaneously Hypertensive Rats | |
| We hypothesized that perinatal inhibition of soluble epoxide hydrolase (EPHX2), which metabolizes epoxyeicosatrienoic acids in the arachidonic acid (AA) cascade, with an orally active EPHX2 inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), would persistently reduce blood pressure (BP) in adult SHR despite discontinuation of AUDA at 4wk of age. Renal Ephx2 gene expression was enhanced in SHR vs. WKY from 2d to 24wk. Effects of perinatal treatment with AUDA, supplied to SHR dams until 4wk after birth, on BP in female and male offspring and renal oxylipin metabolome in female offspring were observed and contrasted to female SHR for direct effects of AUDA (8-12wk). Briefly, inhibition of EPHX2 was effective in persistently reducing BP in female SHR when applied during the perinatal phase. This was accompanied by marked increases in major renal AA epoxides and decreases in renal lipoxygenase products of AA. Early inhibition of EPHX2 induced a delayed increase in renal 5-HETE at 24wk, in contrast to a decrease at 2wk. Inhibition of EPHX2 in female SHR from 8wk to 12wk did not reduce BP, but caused profound decreases in renal 15(S)-HETrE, LTB4, TBX2, 5-HETE and 20-HETE, and increases in TriHOMEs. In male SHR BP reduction after perinatal AUDA was transient. Thus, Ephx2 transcription and EPHX2 activity in early life may initiate mechanisms that eventually contribute to high BP in adult female SHR. However, programmed BP-lowering effects of perinatal EPHX2 inhibition in female SHR cannot be simply explained by persisting reduction in renal EPHX2 activity, but rather by more complex and temporally dynamic interactions between the renal EPHX2, lipoxygenase and cyclooxygenase pathways. | |
| Koeners MP, , et al. Am J Physiol Endocrinol Metab. 2011 Jan 25. [Epub ahead of print] | |
| Soluble epoxide hydrolase: a new target for cardioprotection | |
|
2MPG 2-mercaptopropionyl glycine,
5-HD 5-hydroxydecanoic acid,
14,15-EEZE 14,15-epoxyeicosa-5(Z)-enoic acid,
AUDA .12-(3-adamantan-1-yt-ureido)
dodecanoic acid, cPLA2
cytosolic phosphotipase A2, CYP
Epox cytochrome P-450 epoxygenase,
DHETs dihydroxyeicosatrienoic acids,
mitoKATP mitochondrial
ATP-sensitive potassium channel, mPTP
mitochondrial permeabitity transitionpore,
p-Akt phosphorylated Akt, p-GSK3β
phospho-gtycogen synthase kinase-3β, Pl3K
phosphoinositol-3-kinase, ROS
reactive oxygen species, SarcKATP
sarcolemmal ATP-sensitive potassium channel
|
|
| Gross GJ, Nithipatikom K., et al. Curr Opin Investig Drugs. 2009 Mar;10(3):253-8. | |
 |
Anti Human
EPHX2 IgG Code No.: A00142-01-100 Size: 100 ug Price: $360.00 USD Host: Rabbit Antigen: human EPHX2 Rec. Ab Type: Polyclonal IgG Purification: Protein A Applications: E, IHC Working Dilution: 5 ug/ml) Data Sheet: PDF |
| Human
Soluble Epooxide Hydrolase 2 Recombinant Code No.: 00142-01-100 Size: 100 ug Price: $360.00 USD Protein ID:P34913 Gene ID: 2053 MW:37 KD Tag: His Tag on N-Terminus Expressed: E. Coli Purity: 90% Data Sheet: PDF |
|
|
|
| Name | Code No. |
Size |
Price ($) |
| Soluble Epoxide Hydrolase 2 (Human) recombinant |
00142-01-10 |
10 ug |
80.00 |
| Soluble Epoxide Hydrolase 2 (Human) recombinant |
00142-01-50 |
50 ug |
250.00 |
| Soluble Epoxide Hydrolase 2 (Human) recombinant | 100 ug |
360.00 |
|
| Soluble Epoxide Hydrolase 2 (Human) recombinant |
00142-01-1000 |
1000 ug |
3200.00 |
| Rabbit Anti Soluble EPHX2(Human) IgG | 100 ug |
360.00 |
|